Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 11/20 | 0.38 |
| ▸ | JAK2 | O60674 | 6/20 | 0.38 |
| ▸ | JAK3 | P52333 | 6/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26072351 | 1.00 | CCR2 (0.38) | CCR2JAK2JAK3PTK2CTSS | |
| SCHEMBL29395772 | 0.92 | CCR2 (0.44) | CCR2JAK2JAK3PTK2 | |
| SCHEMBL26072701 | 0.92 | CCR2 (0.44) | CCR2JAK2JAK3PTK2 | |
| SCHEMBL29395751 | 0.88 | CCR2 (0.42) | CCR2JAK2JAK3PTK2 | |
| SCHEMBL26071958 | 0.88 | CCR2 (0.42) | CCR2JAK2JAK3PTK2 | |
| SCHEMBL29395748 | 0.86 | GPR119 (0.43) | CCR2JAK2JAK3PTK2CTSS | |
| SCHEMBL26072716 | 0.86 | GPR119 (0.43) | CCR2JAK2JAK3PTK2CTSS | |
| SCHEMBL31576212 | 0.85 | CCR2 (0.38) | CCR2JAK2JAK3PTK2STAT3 | |
| SCHEMBL26072992 | 0.85 | CCR2 (0.38) | CCR2JAK2JAK3PTK2STAT3 | |
| SCHEMBL29393849 | 0.81 | CCR2 (0.47) | CCR2JAK2JAK3PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590091-B2 | 1H-pyrrolo[3,2-C]pyridine and 1H-pyrrolo[2,3-C]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-03-31 | — | — | US | claimed |
| EP-4200298-B1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2025-05-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590091-B2 | 1H-pyrrolo[3,2-C]pyridine and 1H-pyrrolo[2,3-C]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis | TLR9, TLR1, TLR3 | CCR2 36/4885JAK2 625/4885JAK3 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.